| 000 -LEADER |
|---|
| fixed length control field |
01926nab a22002777a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
200421b2020 xxu||||| |||| 00| 0 eng d |
| 100 ## - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Patil VM |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Beyond conventional chemotherapy, targeted therapy and immunotherapy in squamous cell cancer of the oral cavity |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Date of publication, distribution, etc |
2020 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
|
| 500 ## - GENERAL NOTE |
|---|
| General note |
Address for correspondence: kumarprabhashtmh@gmail.com |
| 520 ## - SUMMARY, ETC. |
|---|
| Summary, etc |
The focus of this review article is to throw light on non-conventional systemic chemotherapy that affects the tumour microenvironment and potentially has a favourable impact on the management of squamous cell cancer of the oral cavity. A metronomic combination of weekly methotrexate and celecoxib seems equally effective to single agent cisplatin in the palliative setting, but needs phase III testing. The same metronomic combination seems inferior to paclitaxel-cetuximab. Triple drug metronomic chemotherapy (methotrexate, celecoxib, and erlotinib) is still under development with promising data from pilot studies. Metronomic chemotherapy also seems beneficial in the curative setting but results of confirmatory studies are eagerly awaited. The low rate of adverse events and low cost make this regimen an attractive alternative. Both in vivo and in-vitro data suggests that numerous drugs like anthelmintics, DMARDs, antimalarials can be repurposed for Head and Neck Cancers. However, there is a dearth of clinical studies reported till date. |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Head and Neck Cancer |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Metronomic chemotherapy |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Oral cancer |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Repurposed |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Noronha V |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Joshi A |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Abhyankar A |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Menon N |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Dhumal S |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Personal name |
Prabhash K |
| Relator term |
Corresponding author |
| 773 ## - HOST ITEM ENTRY |
|---|
| Main entry heading |
Oral Oncology. |
| Place, publisher, and date of publication |
Amsterdam : Elsevier, 2020 |
| Relationship information |
Vol. 105, p. 104673. |
| International Standard Serial Number |
1368-8375 |
| 906 ## - LOCAL DATA ELEMENT F, LDF (RLIN) |
|---|
| Dept |
SO-Head & Neck |
| Corporate name |
TMC |
| PMID |
32272385 |
| Article Type |
Journal Article |
| Country type |
International |
| Added Entry |
TMH - HBNI |
| First Author |
TMH - HBNI |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Item type |
Articles |
